Nakom (Carbidopa, Levodopa)

Carbidopa/Levodopa, the active ingredient in Nakom, is an antiparkinson agent presented as an oral tablet for oral use. It combines levodopa, a dopamine precursor, with carbidopa, an enzyme inhibitor, to increase central dopamine levels and reduce peripheral side effects. The combination is indicated for managing motor deficits in Parkinson's disease and Parkinsonian syndrome in adult patients.

GNH USA supplies Nakom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality compliance with EU standards and reliable global distribution.

Nakom (carbidopa/levodopa) acts on the dopaminergic pathway to improve motor function in Parkinsonian disorders.

- Parkinson's disease: reduces bradykinesia, rigidity and tremor, improving daily motor activities. - Parkinsonian syndrome: alleviates motor symptoms caused by dopamine deficiency in secondary Parkinsonism. - Levodopa‑responsive Parkinsonism: restores dopaminergic transmission to control motor fluctuations.

Common and serious adverse reactions have been reported with carbidopa/levodopa therapy.

Common Side Effects: - Nausea - Vomiting - Orthostatic hypotension - Dizziness - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia - Neuroleptic malignant syndrome - Severe hypotension - Cardiac arrhythmia - Hallucinations - Severe depression

When prescribing Nakom, clinicians should observe several precautionary measures to ensure safe use.

- Monitor blood pressure: watch for orthostatic changes, especially at treatment initiation. - Assess psychiatric status: observe for hallucinations, confusion or mood alterations. - Adjust dose in renal impairment: reduce dosage or increase dosing interval as needed. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal symptoms. - Use with caution in elderly patients: increased sensitivity to side effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Carbidopa/levodopa may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (dopamine antagonists): may diminish therapeutic effect. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors: may enhance dopaminergic activity. - Antihypertensive agents: additive blood pressure lowering. - SSRIs and SNRIs: potential for serotonin syndrome when combined with MAO inhibitors. - Iron or calcium supplements: may reduce levodopa absorption if taken simultaneously.